# A Novel Biomarker for Response and Prognosis of HBV-related Hepatocellular Carcinoma

> **NCT05752890** · — · NOT_YET_RECRUITING · sponsor: **National Taiwan University Hospital** · enrollment: 95 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Hepatitis b Virus
- Radiotherapy
- Biomarker

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05752890
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-03-01
- **Primary completion:** 2031-01-31
- **Final completion:** 2031-01-31
- **Target enrollment:** 95 (ESTIMATED)
- **Last updated:** 2023-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05752890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05752890, "A Novel Biomarker for Response and Prognosis of HBV-related Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05752890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*